The Effects of Storage Time and Repeated Freeze–Thaw Cycles on Intact Fibroblast Growth Factor 23 Levels
Authors:
- 9 February 2021
- journal article
- research article
- Published by SAGE Publications in Biopreservation and Biobanking
- Vol. 19 (1) , 48-52
Abstract
Background: Fibroblast growth factor 23 (FGF23) has become increasingly important in chronic kidney diseases (CKDs), cardiovascular calcification, and metabolic bone diseases. Fresh or stored blood samples are widely used for the FGF23 assay. Clarifying the factors influencing the FGF23 assay can help to quantify FGF23 more accurately. This study explored the effects of low-temperature storage time and repeated freeze–thaw cycles on the measurement of serum intact FGF23 (iFGF23). Materials and Methods: We selected 60 serum samples from patients with CKD stages 3–5 and hemodialysis patients. An enzyme-linked immunosorbent assay was used to measure the changes in serum iFGF23 levels after 6 years of storage at −80°C. In total, 18 fresh serum samples were frozen and thawed for 0, 1, 3, and 5 cycles to explore the effects of repeated freeze–thaw cycles on serum iFGF23 levels. Results: Median serum iFGF23 concentrations were 252.17 (interquartile range [IQR] 113.82–592.38) pg/mL and 203.85 (IQR 64.76–545.39) pg/mL before and after 6 years. There were no significant differences between them. However, we found a downward trend of 48% in the samples close to the normal level of iFGF23 (p = 0.160). In addition, the iFGF23 levels of samples frozen and thawed for 0, 1, 3, and 5 cycles were 278.41 ± 39.51 (mean ± standard deviation) pg/mL, 262.84 ± 38.42 pg/mL, 252.97 ± 34.65 pg/mL and 250.49 ± 37.12 pg/mL, respectively. A slight downward trend in iFGF23 levels was observed with increasing freeze–thaw times; however, no significant differences were found among different freeze–thaw cycles. Conclusion: Serum iFGF23 levels remained stable after storage at −80°C for 6 years. In addition, five freeze–thaw cycles had no significant effects on serum iFGF23 levels.Keywords
This publication has 27 references indexed in Scilit:
- Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney diseaseExperimental Cell Research, 2012
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patientsNephrology Dialysis Transplantation, 2010
- Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul StudyNephrology Dialysis Transplantation, 2009
- Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly populationAtherosclerosis, 2009
- Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney DiseaseCirculation, 2009
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Fibroblast Growth Factor 23: A Possible Cause of Left Ventricular Hypertrophy in Hemodialysis PatientsThe American Journal of the Medical Sciences, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patientsBone, 2008